Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

alrizomadlin (APG-115)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Ascentage Pharma

Drug class:

MDM2 inhibitor

Related drugs:

MDM2 amplification	Liposarcoma	MDM2 amplification	Liposarcoma	APG-115 Sensitive: C2 – Inclusion Criteria APG-115 Sensitive : C2	APG-115 Sensitive: C2 – Inclusion Criteria APG-115 Sensitive : C2
ATM mutation	Solid Tumor	ATM mutation	Solid Tumor	APG-115 Sensitive: C2 – Inclusion Criteria APG-115 Sensitive : C2	APG-115 Sensitive: C2 – Inclusion Criteria APG-115 Sensitive : C2
TP53 wild-type	Salivary Gland Cancer	TP53 wild-type	Salivary Gland Cancer	APG-115 Sensitive: C3 – Early Trials APG-115 Sensitive : C3	APG-115 Sensitive: C3 – Early Trials APG-115 Sensitive : C3
STK11 mutation	Non Small Cell Lung Cancer	STK11 mutation	Non Small Cell Lung Cancer	APG-115 Sensitive: D – Preclinical APG-115 Sensitive : D	APG-115 Sensitive: D – Preclinical APG-115 Sensitive : D
BCL2 overexpression + MCL1 expression	Diffuse Large B Cell Lymphoma	BCL2 overexpression + MCL1 expression	Diffuse Large B Cell Lymphoma	APG-115 + APG-2575 Sensitive: D – Preclinical APG-115 + APG-2575 Sensitive : D	APG-115 + APG-2575 Sensitive: D – Preclinical APG-115 + APG-2575 Sensitive : D
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	olverembatinib + APG-115 Sensitive: D – Preclinical olverembatinib + APG-115 Sensitive : D	olverembatinib + APG-115 Sensitive: D – Preclinical olverembatinib + APG-115 Sensitive : D
TP53 wild-type	Multiple Myeloma	TP53 wild-type	Multiple Myeloma	APG-115 Sensitive: D – Preclinical APG-115 Sensitive : D	APG-115 Sensitive: D – Preclinical APG-115 Sensitive : D
TP53 wild-type	Multiple Myeloma	TP53 wild-type	Multiple Myeloma	bortezomib + APG-115 Sensitive: D – Preclinical bortezomib + APG-115 Sensitive : D	bortezomib + APG-115 Sensitive: D – Preclinical bortezomib + APG-115 Sensitive : D
TP53 wild-type	Breast Cancer	TP53 wild-type	Breast Cancer	KRT-232 + APG-115 Sensitive: D – Preclinical KRT-232 + APG-115 Sensitive : D	KRT-232 + APG-115 Sensitive: D – Preclinical KRT-232 + APG-115 Sensitive : D